SCIENTURE HOLDINGS, INC.

NASDAQ: SCNX (Scienture Holdings, Inc.)

Kemas kini terakhir: 6 hari lalu, 4:56AM

2.90

-0.11 (-3.65%)

Penutupan Terdahulu 3.01
Jumlah Dagangan 4,416
Harga / Jualan (P/S) 3.56
Harga / Buku (P/B) 0.080
Julat 52 Minggu
2.64 (-8%) — 18.75 (546%)
Margin Operasi (TTM) -34,814.94%
EPS Cair (TTM) 0.660
Pertumbuhan Hasil Suku Tahunan (YOY) -58.70%
Jumlah Hutang/Ekuiti (D/E MRQ) 4.70%
Nisbah Semasa (MRQ) 1.05
Aliran Tunai Operasi (OCF TTM) -7.03 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -6.06 M
Pulangan Atas Aset (ROA TTM) -14.99%
Pulangan Atas Ekuiti (ROE TTM) -35.92%

AISkor Stockmoo

-1.5
Pulangan di bawah kos modalnya. Pulangan atas modal meningkat. info
Hutang rendah. Keuntungan lemah. Kecairan jangka pendek nipis. Aliran tunai negatif. info
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Nilai Pegangan info NA
Premium Risiko info NA
Penilaian Pasaran info NA
Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info
Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga hampir dengan purata itu. Dagangan lebih tinggi pada hari harga naik. info
Daripada analisis teknikal AI kami terhadap carta. info NA
Corak Lilin info NA
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Sentimen Pegangan info NA
Sentimen Berita info NA
Institusi bersih +2.54% daripada saham dalam pemfailan 13F terkini: 8 pemegang menambah, 5 mengurang (suku berakhir 30 Sep 2026). info
Kedudukan jual singkat -88.5% dari 31 Aug hingga 30 Oct 2026, 3.1 hari untuk tutup (FINRA). info
Aktiviti Orang Dalam info NA
Persekitaran pasaran berhati-hati. info
Sektor ketinggalan berbanding pasaran.
Tonggak-tonggak sependapat, jadi skor diperkukuh.
Perolehan sesaham turun naik. Mencatat kerugian dalam tahun-tahun kebelakangan. info
Di bawah garis aliran jangka sederhana. info
Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info
Momentum jangka pendek menurun. info
Harga di antara sokongan dan rintangan. Paras sokongan dan rintangan menaik. info
Skor Akhir -1.48
Tunjuk semua

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Pharmaceutical Retailers (US) Bercampur Bercampur
Pharmaceutical Retailers (Global) Bercampur Bercampur
Stok Scienture Holdings, Inc. Bercampur -

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B Skor
SCNX - - - 0.080 -1.5
WBA 10 B 4.34% - 1.44 -2.0
PETS 19 M - - 1.18 -3.9
RDGT 853 K - - 0.020 -2.2
MEDS - - - - -2.1
HITI 199 M - - 2.95 -1.7

Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.

Sektor Healthcare
Industri Pharmaceutical Retailers
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 32.59%
% Dimiliki oleh Institusi 1.35%

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Institusi

Pemilikan institusi: 6.24%

Kedudukan Pemegang Saham
Bertambah 8 41,998
Berkurang 5 7,231
Baharu 2 15,999
Dijual habis 1 5

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 117,350 3.1
15 Oct 2026 105,863 1.0
30 Sep 2026 1,304,235 1.0
15 Sep 2026 1,249,889 1.2
31 Aug 2026 1,022,272 2.6
14 Aug 2026 1,607,698 1.0

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

Tarikh Jenis Butiran
22 Oct 2026 Yahoo Finance SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027
Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Million, Supported by Continued Arbli™ Growth and the Commercial Launch of REZENOPY™ Two FDA-Approved Commercial Products Position Company for Continued Sequential Revenue Growth High Gross Margins and…
13 Oct 2026 Yahoo Finance SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
Continued Arbli™ sales growth, combined with REZENOPY™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth Arbli™ wholesale unit sales increased 74% sequentially, with recent institutional formulary additions supporting continued commercial…
13 Oct 2026 Yahoo Finance EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability
Scienture Holdings Inc. (NASDAQ:SCNX) on Tuesday reported preliminary third-quarter revenue of approximately $1.22 million, up 256% from $344,000 in the previous quarter. The pharmaceutical company’s revenue growth reflected rising sales of its blood pressure medication, Arbli, and initial…
02 Oct 2026 Yahoo Finance SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
Major Institutional Formulary Win Expands Arbli™’s Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially Arbli™ Addresses an Approximately $219 Million U.S. Losartan Market Representing Approximately 72 Million Prescriptions Annually COMMACK, NY, Oct. 02, 2026 (GLOBE…
02 Oct 2026 Yahoo Finance EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions
Scienture Holdings Inc. (NASDAQ:SCNX) on Friday announced that three leading U.S. pediatric academic medical centers added its proprietary hypertension medication to their formularies. These specialized hospitals, which focus on treating children with severe and chronic medical conditions, now…
30 Sep 2026 Yahoo Finance Scienture Holdings, Inc. Announces Reverse Stock Split
COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization…
22 Sep 2026 Yahoo Finance SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
Agreement provides dedicated commercial channel for REZENOPY™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United States According to IQVIA data (MAT July 2026), the U.S. naloxone market generated approximately $140 million…
09 Sep 2026 Yahoo Finance SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
Management to Highlight Growing Commercial Momentum of Arbli™ and the Commercial Launch of REZENOPY™ COMMACK, NY, Sept. 09, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on…
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
19 Jul 2024 08 Jul 2024 24 Jul 2024 1.5 Tunai
25 Mar 2024 28 Feb 2024 22 Mar 2024 8 Tunai

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2024 9.50 2 157.03

Persediaan Teknikal Sederhana

Susunan aliran
Kecerunan
Kemasukan
Dagangan
Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga hampir dengan purata itu. Dagangan lebih tinggi pada hari harga naik.
Sokongan terdekat: 2.73 – 2.89 · paras sederhana
Rintangan terdekat: 3.15 – 3.31 · paras sederhana

AI Analisis Teknikal

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Risiko / Ganjaran
TP1:
TP2:

Kerugian hingga SL berbanding keuntungan hingga setiap sasaran, dari EP. Nisbah 2 atau lebih biasanya dicari.

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda